BRIEF published on 10/24/2024 at 09:35, 1 month 28 days ago QUANTRO Therapeutics and IMP Form Research Alliance for Drug Discovery Drug Discovery Cancer Therapy QUANTRO Therapeutics IMP Collaboration Transcription Factor
PRESS RELEASE published on 10/24/2024 at 09:30, 1 month 28 days ago QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery QUANTRO Therapeutics partners with IMP to advance transcriptomic drug discovery. Strategic collaboration to explore transcription factors' functions for cancer therapies QUANTRO Therapeutics Transcription Factors IMP Transcriptomic Drug Discovery Cancer Therapies
BRIEF published on 08/06/2024 at 10:05, 4 months 15 days ago QUANTRO Therapeutics Secures Key Austrian Research Grant to Advance Platform Development Drug Discovery QUANTRO Therapeutics FFG Grant Transcriptomic Platform Multiplexing
PRESS RELEASE published on 08/06/2024 at 10:00, 4 months 15 days ago QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform QUANTRO Therapeutics secures Austrian research grant to accelerate cutting-edge platform development, enabling multiplex target screening in drug discovery Drug Discovery QUANTRO Therapeutics Austrian Research Grant Transcriptomic Discovery Platform Multiplexing Capabilities
BRIEF published on 06/04/2024 at 23:12, 6 months 16 days ago QUANTRO Therapeutics Reaches Milestone in Collaboration with Boehringer Ingelheim Cancer Treatments R&D Collaboration Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors
PRESS RELEASE published on 06/04/2024 at 23:07, 6 months 16 days ago QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments QUANTRO Therapeutics achieves key milestone in collaboration with Boehringer Ingelheim for first-in-class cancer treatments using proprietary technology Cancer Treatments Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors R&D Program
PRESS RELEASE published on 04/04/2023 at 09:30, 1 year 8 months ago QUANTRO Therapeutics appoints Industry Expert Dr. Michael Bauer as Chief Executive Officer
Published on 12/21/2024 at 01:30, 17 hours 40 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 40 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 5 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 40 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 19 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 25 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 6 hours 52 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago Share capital decrease by way of treasury shares cancellation
